- Robin Arya | GoalFi
- Posts
- 🌟 Stock of the Week: Glenmark Pharmaceuticals Ltd.
🌟 Stock of the Week: Glenmark Pharmaceuticals Ltd.
📉 GoalFi Stock of the Week – July 13, 2025
GoalFi Social
July 13, 2025
Hello ,
Every week, we spotlight a standout stock driven not just by momentum, but by strong fundamentals, factor-based signals, and powerful catalysts.
This week, our spotlight is on Glenmark Pharmaceuticals Ltd., a research-led global pharma company witnessing a major rerating in the market after a transformative licensing deal.
🌟 Stock of the Week: Glenmark Pharmaceuticals Ltd.
📅 Featured in: GoalFi – Momentum Select 10 Portfolio & other high-conviction baskets
🚀 Return Since Entry (24-Jun): +24.68% in less than 3 weeks
📈 Gained +14.55% on Friday | Weekly Gain: +19.16% | MTD Gain: +24.36%
🧬 About Glenmark Pharma
💼 Company Profile
Glenmark Pharmaceuticals Ltd. is a global research-led pharmaceutical company with a strong portfolio across generics, specialty and OTC segments. It operates in over 80 countries and is known for leadership in dermatology, respiratory, and oncology.
14th largest pharma player in India
15th largest generic player in USA
RYALTRIS, their flagship product, is marketed in 70+ countries
🔍 Why Glenmark? What Triggered the Rally?
✅ $700 Million Deal with AbbVie
Glenmark’s US-based subsidiary, Ichnos Sciences, struck a landmark global licensing deal for its cancer drug ISB-2001 with global pharma giant AbbVie. The deal includes:
$700 million upfront payment
Up to $1.2 billion in milestone-based payouts
Ongoing royalties from commercialisation
✅ Institutional Accumulation
Mutual Funds and FIIs significantly increased their stakes. DIIs now hold 14.6%, up from 10.5%, while FIIs own 23.15%. This shows growing institutional conviction in Glenmark's innovation and earnings trajectory.
✅ Strong Technical & Momentum Breakout
Glenmark hit a new 52-week high of ₹2,286, and triggered momentum-based entries across smart-beta portfolios, including GoalFi's Momentum Select 10.
💼 Quarterly & Annual Financials (Consolidated)
Q4 FY25 vs Q4 FY24
Metric | Q4 FY25 | Q4 FY24 |
|---|---|---|
Revenue (₹ Cr) | 3,256 | 3,063 |
Net Profit (₹ Cr) | 4.38 | -1,214.27 |
EPS (₹) | 0.16 | -43.17 |
OPM % | 17.23% | 16.47% |
FY25 vs FY24
Metric | FY25 | FY24 |
|---|---|---|
Revenue (₹ Cr) | 13,322 | 11,813 |
Net Profit (₹ Cr) | 1,047 | -1,434 |
EPS (₹) | 37.11 | -53.22 |
Operating Margin | 18% | 10% |
ROE | 16% | Negative |
📈 Long-Term Growth Metrics
Metric | 10Y | 5Y | 3Y | TTM |
|---|---|---|---|---|
Sales CAGR | 7% | 5% | 3% | 13% |
Profit CAGR | 17% | 12% | 6% | 130% |
Stock Price CAGR | 7% | 39% | 78% | 58% |
Return on Equity | 6% | -1% | -10% | 16% |
Category | Shareholding |
|---|---|
Promoters | 46.65% |
FIIs | 23.15% |
DIIs | 14.60% |
Public | 15.56% |
[GoalFi] Momentum Select 10 - Small Cap Model: A Momentum-focused factor strategy selecting fundamentally strong, undervalued stocks from Nifty Smallcap 250
✅ GoalFi View
Glenmark Pharma is a prime example of "earnings-led momentum meets innovation". The strategic AbbVie licensing deal, improving fundamentals, and rising institutional participation mark the beginning of what could be a re-rating journey.
📣 Stay Ahead with GoalFi
Make sure to explore our curated portfolios that align with your financial goals.
Explore GoalFi Smallcases here: https://goalfiresearch.smallcase.com
We hope this update helps you stay informed and empowered in your investment journey. Feel free to reach out if you have any questions or need personalized advice.
Best Regards,
Team GoalFi
Disclosures: https://goalfiresearch.smallcase.com/#disclosures
Disclaimer: This newsletter is intended solely for educational and informational use. It does not constitute financial advice or serve as a promotional message.